- Home
- ACOG
as 05-09-2025 4:00pm EST
Stocks
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Upcoming Earnings Alert:
Get ready for potential market movements as Alpha Cognition Inc. Common Stock ACOG prepares to release earnings report on 15 May 2025.
| Founded: | 2000 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 80.3M | IPO Year: | N/A |
| Target Price: | $20.00 | AVG Volume (30 days): | 80.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.75 - $7.00 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Alpha Cognition Inc. Common Stock News
ACOG Breaking Stock News: Dive into ACOG Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
Newsfile
9 days ago
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Business Wire
11 days ago
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
Business Wire
a month ago
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
Newsfile
a month ago
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Business Wire
a month ago
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
Business Wire
2 months ago
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
MT Newswires
2 months ago
Alpha Cognition Launches Zunveyl for Treating Alzheimer's Disease; Shares Up Pre-Bell
Compare ACOG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACOG Alpha Cognition Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.